Published in Alzheimer Dis Assoc Disord on January 10, 2000
Blood-brain barrier permeability abnormalities in vascular cognitive impairment. Stroke (2011) 1.60
Multimodal markers of inflammation in the subcortical ischemic vascular disease type of vascular cognitive impairment. Stroke (2014) 0.96
Cerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimer's disease. J Cereb Blood Flow Metab (2015) 0.86
Cerebrospinal fluid analysis should be considered in patients with cognitive problems. Int J Alzheimers Dis (2010) 0.82
Validation of biomarkers in subcortical ischaemic vascular disease of the Binswanger type: approach to targeted treatment trials. J Neurol Neurosurg Psychiatry (2015) 0.80
An overview of biomarkers in Alzheimer's disease. Ann Indian Acad Neurol (2010) 0.76
Jobelyn® Supplement Lowered Neuronal Degeneration: Significance of Altered p53 and ɤ-Enolase Protein Expressions in Prefrontal Cortex of Rat Exposed to Ethanol. Ann Neurosci (2016) 0.75
Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer's Disease. Int J Mol Sci (2017) 0.75
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med (2004) 16.58
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology (2009) 5.94
Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol (1999) 3.62
Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol (2001) 3.19
CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology (2003) 3.18
Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology (1999) 2.74
Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett (2000) 2.25
Robust and accurate single nucleotide polymorphism genotyping by dynamic allele-specific hybridization (DASH): design criteria and assay validation. Genome Res (2001) 2.19
Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann N Y Acad Sci (2007) 2.11
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett (2001) 2.05
Incidence and pathogenesis of clinical relapse after herpes simplex encephalitis in adults. J Neurol (2005) 2.04
Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett (2001) 1.89
Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem (2001) 1.87
Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology (2003) 1.85
CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus. Acta Neurol Scand (2007) 1.85
Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry (1998) 1.83
Gamma-secretase-dependent amyloid-beta is increased in Niemann-Pick type C: a cross-sectional study. Neurology (2010) 1.78
Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid (2000) 1.75
CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology (2005) 1.73
Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol (1999) 1.68
Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord (2003) 1.67
A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem (2009) 1.66
Cerebrospinal fluid biomarkers of white matter lesions - cross-sectional results from the LADIS study. Eur J Neurol (2009) 1.64
Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology (2011) 1.63
Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry (2003) 1.62
Brain-specific proteins in the cerebrospinal fluid of severely asphyxiated newborn infants. Acta Paediatr (2001) 1.60
CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology (2002) 1.58
New evidence for an association between the CSF HVA:5-HIAA ratio and psychopathic traits. J Neurol Neurosurg Psychiatry (2003) 1.58
Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke (1995) 1.58
Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry (2004) 1.53
Intrathecal release of pro- and anti-inflammatory cytokines during stroke. Clin Exp Immunol (1997) 1.51
A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia. Neurology (1998) 1.50
Brain specific proteins in posthaemorrhagic ventricular dilatation. Arch Dis Child Fetal Neonatal Ed (2001) 1.46
Altered blood-brain-barrier function in Alzheimer's disease? Acta Neurol Scand (1994) 1.44
Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology (2007) 1.43
Cerebrospinal fluid monoamine metabolites and atmospheric pressure. Biol Psychiatry (1996) 1.39
Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport (1999) 1.38
Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology (2006) 1.37
APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology (2004) 1.33
Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett (1999) 1.32
Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res (2005) 1.32
Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology (2012) 1.31
Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry (2001) 1.26
Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection. Neurology (2007) 1.21
Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer's disease. Exp Neurol (1998) 1.21
CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm (Vienna) (2000) 1.20
Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome. J Neurol Sci (2005) 1.20
Serum levels of the brain-derived proteins S-100 and NSE predict long-term outcome after cardiac arrest. Resuscitation (2001) 1.20
Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res (2001) 1.19
Neurochemical dissection of synaptic pathology in Alzheimer's disease. Int Psychogeriatr (1998) 1.18
CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology (2010) 1.18
Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology (2004) 1.17
Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease. Neurobiol Aging (2007) 1.17
Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J Alzheimers Dis (2000) 1.13
CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement Geriatr Cogn Disord (2006) 1.13
Serum levels of S100B, S100A1B and S100BB are all related to outcome after severe traumatic brain injury. Acta Neurochir (Wien) (2008) 1.12
Increased levels of GFAP in the cerebrospinal fluid in three subtypes of genetically confirmed Alexander disease. Neuropediatrics (2005) 1.12
CSF studies in violent offenders. I. 5-HIAA as a negative and HVA as a positive predictor of psychopathy. J Neural Transm (Vienna) (2001) 1.11
Neurofilament protein levels in CSF are increased in dementia. Neurology (1999) 1.11
Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord (2001) 1.10
Local and systemic GM-CSF increase in Alzheimer's disease and vascular dementia. Acta Neurol Scand (2001) 1.10
Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-arrestin1. Oncogene (2007) 1.10
Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology (1999) 1.09
Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. Eur J Neurol (2007) 1.08
Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology (2000) 1.07
Harmonized diagnostic criteria for Alzheimer's disease: recommendations. J Intern Med (2014) 1.07
Glial fibrillary acidic protein is increased in the cerebrospinal fluid of preterm infants with abnormal neurological findings. Acta Paediatr (1996) 1.06
Symptoms, vascular risk factors and blood-brain barrier function in relation to CT white-matter changes in dementia. Eur Neurol (2000) 1.06
Blood brain barrier function in vascular dementia. Acta Neurol Scand (1990) 1.06
Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease. Dement Geriatr Cogn Disord (2003) 1.05
Increased intrathecal inflammatory activity in frontotemporal dementia: pathophysiological implications. J Neurol Neurosurg Psychiatry (2004) 1.04
Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory study. Dement Geriatr Cogn Disord (2010) 1.04
Measurement of apolipoprotein E (apoE) in cerebrospinal fluid. Neurochem Res (2000) 1.03
A population study of apoE genotype at the age of 85: relation to dementia, cerebrovascular disease, and mortality. J Neurol Neurosurg Psychiatry (1998) 1.02
Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease. Neurosci Lett (2001) 1.01
Increased serum levels of the S-100 protein are associated with hypoxic brain damage after cardiac arrest. Stroke (1998) 1.01
S-100 protein in melanocytic tumors. An immunohistochemical investigation of benign and malignant melanocytic tumors and metastases of malignant melanoma and a characterization of the antigen in comparison to human brain. Acta Pathol Microbiol Immunol Scand A (1984) 1.00
Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. Neurology (2007) 0.99
Evaluation of CSF biomarkers for axonal and neuronal degeneration, gliosis, and beta-amyloid metabolism in Alzheimer's disease. J Neurol Neurosurg Psychiatry (2001) 0.99
Lack of replication of association findings in complex disease: an analysis of 15 polymorphisms in prior candidate genes for sporadic Alzheimer's disease. Eur J Hum Genet (2001) 0.98
Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study. Neurology (2005) 0.98
Markers of nerve tissue injury in the cerebrospinal fluid in patients with lumbar disc herniation and sciatica. Spine (Phila Pa 1976) (1999) 0.97
Clinic-based cases with frontotemporal dementia show increased cerebrospinal fluid tau and high apolipoprotein E epsilon4 frequency, but no tau gene mutations. Exp Neurol (2001) 0.97
Intrathecal immune activation is associated with cerebrospinal fluid markers of neuronal destruction in AIDS patients. J Neuroimmunol (2000) 0.97
Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity. J Neural Transm (Vienna) (2003) 0.97
Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders. Mech Ageing Dev (2001) 0.96
Increased cerebrospinal fluid protein tau concentration in neuro-AIDS. J Neurol Sci (1999) 0.96